Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Allergan

NEW YORK, NY / ACCESSWIRE / February 14, 2017 /
Promises of a “phenomenal” tax plan by President Trump continued to push markets to new record highs on Monday. The Dow Jones industrial Average gained 0.70 percent, 142.79 points, to close at 20,412.16, while the S&P 500 gained 0.52 percent to close at 2,328.25. On Monday, the S&P 500 hit a $20 trillion market cap for the first time in History after it broke the 2,324.22 mark, according to Howard Silverblatt, senior Index analyst at S&P Dow Jones Indices. Currently, the S&P 500 is trading at approximately 17.45 times its 12 month forward earning, 25 year average of price to forward earnings of the index is near about 15, according to Thomson Reuters.

“Even though we have social unrest and building geopolitical tensions, the market refuses to fall in any meaningful fashion, which means there remains a very strong underlying bid in the market,” said Adam Sarhan, Chief Executive Officer of 50 Park Investments. “This is due to a confluence of a few factors, including the earnings recession being over, a very strong bull market, and the hope for future prosperity under the pro-growth policies of the new administration.”

Let’s Take a
Closer Look at Today’s Trending Tickers

Teva Pharmaceutical’s shares spiked 5.26 percent to close at $34.00 a share on Monday. The stock traded between $33.25 and $34.95 on volume of 22.87 million shares traded. The company reported adjusted earnings of $1.38 a share for the fourth quarter of 2016, compared to $1.28 a share in the fourth quarter of 2015. Revenues totaled $6.49 billion for the fourth quarter of 2016, an increase of 33 percent year-over-year, primarily helped by inclusion of $630 million from the Actavis acquisition. Analysts’ expectations had called for earnings of $1.35 a share on revenues of $6.24 billion, according to analysts’ surveyed by Thomson Reuters. The company’s long-term debt totaled $39.38 billion as of December 31st, 2016, up from $11.3 billion a year ago. The company expects revenue for full year of 2017 to be in range of $23.8 billion to $24.5 billion and also reaffirmed their expectations of Non-GAAP EPS in the range of $4.90 to $5.30 for full year of 2017.

“In 2017, our main focus will be extracting synergies related to the Actavis Generics transaction, driving additional efficiencies throughout the organization, supporting cash generation and paying down our debt to maintain a strong balance sheet and delivering on the promise of the specialty pipeline and key generic launches,” said Yitzhak Peterburg, Interim President and CEO of Teva, in the earnings release.

Access Today’s Teva Pharmaceutical Research
Report Click Here

Allergan’s shares declined increase 0.16 percent to close at $246.76 a share on Monday. The stock traded between $245.90 and $249.60 on volume 3.03 million shares traded. The company has announced that it has entered into a definitive agreement to acquire ZELTIQ Aesthetics, Inc. and its proprietary controlled-cooling technology platform for $56.50 per share, or $2.475 billion. ZELTIQ’s flagship CoolSculpting System is FDA-cleared to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology.

“The acquisition of ZELTIQ is highly complementary and strategic to Allergan. By adding the best-in-class body contouring CoolSculpting System to our best-in-class facial aesthetics, plastic surgery and regenerative medicine offerings we are creating a world-class aesthetics business,” said Brent Saunders, Chairman and CEO of Allergan. “With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices, putting Allergan in a unique position to provide expanded customer service, and help meet the needs of patients.”

Access Today’s Allergan Research Report
Click Here

Today’s Features Includes:

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)

Allergan plc (NYSE: AGN)

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 455087

Go Top